Skip to content

Influencing Factors of Therapeutic Efficacy of Short-Term Spinal Cord Stimulation for Herpes Zoster Neuralgia and Construction of a Nomogram Prediction Model

Influencing Factors of Therapeutic Efficacy of Short-Term Spinal Cord Stimulation for Herpes Zoster Neuralgia and Construction of a Nomogram Prediction Model

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500111989
Enrollment
Unknown
Registered
2025-11-09
Start date
2023-03-01
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Herpes zoster neuralgia

Interventions

Observation Group of Short-Term Spinal Cord Stimulation for Herpes Zoster Neuralgia:None

Sponsors

First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Meets domestic latest diagnostic criteria for herpes zoster-related neuralgia; 2.Age >=18 years; 3.Unresponsive to pharmacological therapy; 4.No history of opioid abuse; 5.Capable of understanding and completing self-assessment scales; 6.Patient agrees to participate in the study and signs relevant informed consent documents.

Exclusion criteria

Exclusion criteria: 1. Loss of sensation in the area of pain; 2. Spinal lesions or deformities that prevent electrode implantation; 3. The presence of tumor or tuberculosis at the puncture site or in the spinal canal; 4. Presence of systemic active infection or localized infection at the puncture site; 5. With serious coagulation abnormality or undergoing anticoagulation therapy; 6. Combined vital organ insufficiency or cancer unable to tolerate surgery; 7. Intellectual or psychiatric anomalies that prevent adequate comprehension of the self-assessment scale; 8. Pregnant or breastfeeding women and those on hormone therapy; 9. Those who are allergic to local anesthetics or therapeutic drugs or with other neuropathic pain.

Design outcomes

Primary

MeasureTime frame
Visual analogue scoring;Disease duration;

Secondary

MeasureTime frame
Serum Albumin;

Countries

China

Contacts

Public ContactPenghui Ke

First Affiliated Hospital of Anhui Medical University

864040149@qq.com+86 63236507

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026